146062-44-4
Chemical Structure
Leriglitazone
Synonym(s): MIN-102; Hydroxypioglitazone
- CAS No.: 146062-44-4
- Formula:C19H20N2O4S
- Molecular Weight:372.44
IUPAC Name: 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione
InChIKey: OXVFDZYQLGRLCD-UHFFFAOYSA-N
SMILES: O=C(N1)SC(CC2=CC=C(OCCC3=NC=C(C(O)C)C=C3)C=C2)C1=O
Biological Activity: Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Leriglitazone | 99.23% | Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Leriglitazone-d4 | Leriglitazone-d4 (MIN-102-d4; Hydroxypioglitazone-d4) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Santambrogio P, et al PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes. Pharmaceutics. 2023 Jan 6;15(1):202. [Content Brief]
- [2]. Rodríguez-Pascau L, et al. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia. Neurobiol Dis. 2021 Jan;148:105162. [Content Brief]
- [3]. Musokhranova U, et al. Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome. J Transl Med. 2023 Oct 26;21(1):756. [Content Brief]
- [4]. Pizcueta P, et al. Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. Int J Mol Sci. 2023 Feb 6;24(4):3201. [Content Brief]
Keywords
